These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30675823)

  • 21. How to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?
    Svennebring AM
    Future Med Chem; 2015; 7(3):259-67. PubMed ID: 25826359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico approaches for predicting ADME properties of drugs.
    Yamashita F; Hashida M
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):327-38. PubMed ID: 15548844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery.
    Chen EP; Bondi RW; Michalski PJ
    J Med Chem; 2021 Mar; 64(6):3185-3196. PubMed ID: 33719432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADME-Space: a new tool for medicinal chemists to explore ADME properties.
    Bocci G; Carosati E; Vayer P; Arrault A; Lozano S; Cruciani G
    Sci Rep; 2017 Jul; 7(1):6359. PubMed ID: 28743970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addressing the challenges of low clearance in drug research.
    Di L; Obach RS
    AAPS J; 2015 Mar; 17(2):352-7. PubMed ID: 25567366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational prediction of formulation strategies for beyond-rule-of-5 compounds.
    Bergström CAS; Charman WN; Porter CJH
    Adv Drug Deliv Rev; 2016 Jun; 101():6-21. PubMed ID: 26928657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling of activity landscapes for drug discovery.
    Bajorath J
    Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2010 Jun; 1(6):435-49. PubMed ID: 22778837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of preformulation on drug development.
    Bharate SS; Vishwakarma RA
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1239-57. PubMed ID: 23534681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving molecules using multi-objective optimization: applying to ADME/Tox.
    Ekins S; Honeycutt JD; Metz JT
    Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive approaches to increase absorption of compounds during lead optimisation.
    Valko K; Butler J; Eddershaw P
    Expert Opin Drug Discov; 2013 Oct; 8(10):1225-38. PubMed ID: 23865945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational modeling of human oral bioavailability: what will be next?
    Cabrera-Pérez MÁ; Pham-The H
    Expert Opin Drug Discov; 2018 Jun; 13(6):509-521. PubMed ID: 29663836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery.
    Shi J; Zha W
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):135-137. PubMed ID: 30136219
    [No Abstract]   [Full Text] [Related]  

  • 38. The graphical representation of ADME-related molecule properties for medicinal chemists.
    Ritchie TJ; Ertl P; Lewis R
    Drug Discov Today; 2011 Jan; 16(1-2):65-72. PubMed ID: 21074634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-like property concepts in pharmaceutical design.
    Di L; Kerns EH; Carter GT
    Curr Pharm Des; 2009; 15(19):2184-94. PubMed ID: 19601822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery.
    Segall MD; Beresford AP; Gola JM; Hawksley D; Tarbit MH
    Expert Opin Drug Metab Toxicol; 2006 Apr; 2(2):325-37. PubMed ID: 16866617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.